Alterola Biotech, Inc.
ABTI
$0.00
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.49M | 2.15M | 2.07M | 1.88M | 1.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.55M | 2.20M | 2.10M | 2.03M | 1.46M |
| Operating Income | -2.55M | -2.20M | -2.10M | -2.03M | -1.46M |
| Income Before Tax | -2.97M | -2.30M | -2.09M | -2.63M | -1.36M |
| Income Tax Expenses | 0.00 | 0.00 | 0.00 | 296.10K | 95.50K |
| Earnings from Continuing Operations | -2.97 | -2.30 | -2.09 | -2.93 | -1.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 107.40K | -- | -- | -- | -- |
| Net Income | -2.87M | -2.30M | -2.09M | -2.93M | -1.45M |
| EBIT | -2.55M | -2.20M | -2.10M | -2.03M | -1.46M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 5.52B | 4.86B | 4.23B | 3.68B | 3.22B |
| Average Diluted Shares Outstanding | 5.52B | 4.86B | 4.23B | 3.68B | 3.22B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |